JP2016510738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510738A5 JP2016510738A5 JP2015561314A JP2015561314A JP2016510738A5 JP 2016510738 A5 JP2016510738 A5 JP 2016510738A5 JP 2015561314 A JP2015561314 A JP 2015561314A JP 2015561314 A JP2015561314 A JP 2015561314A JP 2016510738 A5 JP2016510738 A5 JP 2016510738A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- continuous infusion
- oral
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001802 infusion Methods 0.000 claims description 24
- 229960001080 cangrelor Drugs 0.000 claims description 23
- PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 claims description 23
- 229960002528 ticagrelor Drugs 0.000 claims description 17
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims description 17
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 13
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 5
- 239000005465 B01AC22 - Prasugrel Substances 0.000 claims description 5
- 229960003009 clopidogrel Drugs 0.000 claims description 5
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 5
- 229960004197 prasugrel Drugs 0.000 claims description 5
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000008355 dextrose injection Substances 0.000 claims description 4
- 239000008354 sodium chloride injection Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims 15
- 238000001356 surgical procedure Methods 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- NXAYYSHEARRBLR-UHFFFAOYSA-N 7-(3,5-diethyl-1-methylpyrazol-4-yl)-1-(2-morpholin-4-ylethyl)-3-(3-naphthalen-1-yloxypropyl)indole-2-carboxylic acid Chemical compound CCc1nn(C)c(CC)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(O)=O)n(CCN3CCOCC3)c12 NXAYYSHEARRBLR-UHFFFAOYSA-N 0.000 claims 1
- 239000002172 P2Y12 inhibitor Substances 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/792,056 US9427448B2 (en) | 2009-11-11 | 2013-03-09 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US13/792,056 | 2013-03-09 | ||
| US201361815735P | 2013-04-25 | 2013-04-25 | |
| US61/815,735 | 2013-04-25 | ||
| PCT/US2013/043136 WO2014143107A1 (en) | 2013-03-09 | 2013-05-29 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017197488A Division JP2018002739A (ja) | 2013-03-09 | 2017-10-11 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510738A JP2016510738A (ja) | 2016-04-11 |
| JP2016510738A5 true JP2016510738A5 (OSRAM) | 2016-07-14 |
| JP6247708B2 JP6247708B2 (ja) | 2017-12-13 |
Family
ID=51537409
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561314A Active JP6247708B2 (ja) | 2013-03-09 | 2013-05-29 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
| JP2017197488A Withdrawn JP2018002739A (ja) | 2013-03-09 | 2017-10-11 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
| JP2019137721A Active JP6840197B2 (ja) | 2013-03-09 | 2019-07-26 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017197488A Withdrawn JP2018002739A (ja) | 2013-03-09 | 2017-10-11 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
| JP2019137721A Active JP6840197B2 (ja) | 2013-03-09 | 2019-07-26 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2964233B1 (OSRAM) |
| JP (3) | JP6247708B2 (OSRAM) |
| CN (2) | CN106102750A (OSRAM) |
| AU (1) | AU2013381855B2 (OSRAM) |
| BR (1) | BR112015022070B1 (OSRAM) |
| CA (1) | CA2904523C (OSRAM) |
| EA (1) | EA034550B1 (OSRAM) |
| ES (1) | ES2904256T3 (OSRAM) |
| PL (1) | PL2964233T3 (OSRAM) |
| WO (1) | WO2014143107A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022070B1 (pt) * | 2013-03-09 | 2022-01-18 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor |
| CN110740736A (zh) * | 2017-06-23 | 2020-01-31 | 奇斯药制品公司 | 预防体-肺动脉分流术血栓形成的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL175623B1 (pl) | 1993-02-10 | 1999-01-29 | Astra Pharma Prod | N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca |
| ID21635A (id) | 1996-12-20 | 1999-07-08 | Astra Pharma Prod | Komposisi farmasi untuk pengeringan beku |
| SE9702680D0 (sv) | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
| SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| WO2009140092A1 (en) * | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20100297675A1 (en) * | 2008-11-24 | 2010-11-25 | Huayun Deng | Substrate and method for culturing breast cells |
| EP2384196B1 (en) * | 2008-12-30 | 2017-09-13 | Johansson, Pär | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
| EP2443120B1 (en) * | 2009-06-16 | 2016-11-02 | RSPR Pharma AB | Crystalline form of pemirolast |
| HRP20200445T1 (hr) * | 2009-11-11 | 2020-06-12 | Chiesi Farmaceutici S.P.A. | Metode liječenja ili prevencije tromboze u stentu |
| BR112015022070B1 (pt) * | 2013-03-09 | 2022-01-18 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor |
-
2013
- 2013-05-29 BR BR112015022070-3A patent/BR112015022070B1/pt active IP Right Grant
- 2013-05-29 PL PL13878203T patent/PL2964233T3/pl unknown
- 2013-05-29 CN CN201380076382.XA patent/CN106102750A/zh active Pending
- 2013-05-29 EA EA201591683A patent/EA034550B1/ru unknown
- 2013-05-29 JP JP2015561314A patent/JP6247708B2/ja active Active
- 2013-05-29 ES ES13878203T patent/ES2904256T3/es active Active
- 2013-05-29 EP EP13878203.2A patent/EP2964233B1/en active Active
- 2013-05-29 WO PCT/US2013/043136 patent/WO2014143107A1/en not_active Ceased
- 2013-05-29 EP EP21205348.2A patent/EP3978002A1/en active Pending
- 2013-05-29 CN CN202210682855.1A patent/CN115120606A/zh active Pending
- 2013-05-29 AU AU2013381855A patent/AU2013381855B2/en active Active
- 2013-05-29 CA CA2904523A patent/CA2904523C/en active Active
-
2017
- 2017-10-11 JP JP2017197488A patent/JP2018002739A/ja not_active Withdrawn
-
2019
- 2019-07-26 JP JP2019137721A patent/JP6840197B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514534A5 (OSRAM) | ||
| JP2011520899A5 (OSRAM) | ||
| IL314873A (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| JP2013522303A5 (OSRAM) | ||
| JPWO2020111018A5 (OSRAM) | ||
| JP2019501881A5 (OSRAM) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2018526460A5 (OSRAM) | ||
| JP2016515586A5 (OSRAM) | ||
| JP2016516773A5 (OSRAM) | ||
| JP2017501154A5 (OSRAM) | ||
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP6359583B2 (ja) | 肝細胞がんの予防及び／又は治療のための医薬 | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2024028652A (ja) | 造影剤誘発急性腎障害の予防および／または処置 | |
| JP2016505050A5 (OSRAM) | ||
| JP2020510043A5 (OSRAM) | ||
| JP2019507786A5 (OSRAM) | ||
| JP2016510738A5 (OSRAM) | ||
| JP2019178177A5 (OSRAM) | ||
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| JP7758655B2 (ja) | 組合せ | |
| CN113876775A (zh) | 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途 | |
| JP2019535830A5 (OSRAM) |